We are live on ! Find out more
Ken Griffin

Ken Griffin Citadel Advisors

AUM $875B
1-Year Est. Return 40.91%
 

Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.

This Fund
S&P 500
This Quarter Est. Return
-1.7%
1 Year Est. Return
+40.91%
3 Year Est. Return
+115.85%
5 Year Est. Return
+132.1%
10 Year Est. Return
+518.81%
AUM
$439B
AUM Growth
+$49B
Cap. Flow
+$65.7B
Cap. Flow %
14.98%
Top 10 Hldgs %
33.97%
Holding
14,356
New
1,622
Increased
5,458
Reduced
5,222
Closed
1,858

Top Buys

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$703M
2
TSLA icon
Tesla
TSLA
+$585M
3
JPM icon
JPMorgan Chase
JPM
+$582M
4
AMZN icon
Amazon
AMZN
+$566M
5
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$466M

Top Sells

Rank Stock Value
1
META icon
Meta Platforms (Facebook)
META
+$349M
2
HD icon
Home Depot
HD
+$334M
3
TMUS icon
T-Mobile US
TMUS
+$270M
4
CI icon
Cigna
CI
+$258M
5
CDW icon
CDW
CDW
+$237M

Sector Composition

Rank Sector Weight
1 Technology 3.12%
2 Healthcare 2.55%
3 Financials 2.39%
4 Consumer Discretionary 2.14%
5 Industrials 1.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GROM
12226
DELISTED
Grom Social Enterprises Inc. Common Stock
GROM
$9K ﹤0.01%
+46
New +$10.9K
QNGY
12227
DELISTED
Quanergy Systems, Inc.
QNGY
$9K ﹤0.01%
+2,272
New +$14.7K
NAVB
12228
CALL
DELISTED
Navidea Biopharmaceuticals Inc.
NAVB
$9K ﹤0.01%
34,100
+7,900
+30% +$3.69K
APRE icon
12229
PUT
Aprea Therapeutics
APRE
$8.42M
$8K ﹤0.01%
590
-10
-2% -$177
FRMM
12230
PUT
Forum Markets
FRMM
$80.4M
$8K ﹤0.01%
3
-3
-50% -$10.9K
CRIS icon
12231
PUT
Curis
CRIS
$3.76M
$8K ﹤0.01%
29
-3
-9% -$1.21K
LODE icon
12232
PUT
Comstock
LODE
$263M
$8K ﹤0.01%
1,900
-480
-20% -$2.67K
PTPI
12233
CALL
DELISTED
Petros Pharmaceuticals
PTPI
$8K ﹤0.01%
60
+2
+3% +$363
SYRE icon
12234
CALL
Spyre Therapeutics
SYRE
$9.14B
$8K ﹤0.01%
604
-1,164
-66% -$14.4K
UAMY icon
12235
PUT
United States Antimony
UAMY
$825M
$8K ﹤0.01%
20,400
-3,300
-14% -$1.44K
XYLO
12236
DELISTED
Xylo Technologies
XYLO
$8K ﹤0.01%
+380
New +$9.26K
DNA.WS
12237
DELISTED
Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share
DNA.WS
$8K ﹤0.01%
10,723
-1,768
-14% -$1.21K
SPECW
12238
DELISTED
Spectaire Holdings, Inc. Warrant
SPECW
$8K ﹤0.01%
155,858
+1,410
+0.9% +$88
AEON.WS
12239
DELISTED
AEON Biopharma Inc
AEON.WS
$8K ﹤0.01%
117,964
-2,622
-2% -$239
FOXWW
12240
DELISTED
FoxWayne Enterprises Acquisition Corp. Warrant
FOXWW
$8K ﹤0.01%
84,420
+502
+0.6% +$23
FCAX.WS
12241
DELISTED
Fortress Capital Acquisition Corp. Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
FCAX.WS
$8K ﹤0.01%
112,000
-4,763
-4% -$561
REVHW
12242
DELISTED
Revolution Healthcare Acquisition Corp. SAIL Warrant.
REVHW
$8K ﹤0.01%
200,001
– –
ONCS
12243
DELISTED
OncoSec Medical Incorporated
ONCS
$8K ﹤0.01%
711
-1,686
-70% -$25.3K
IGC icon
12244
IGC Pharma
IGC
$31.1M
$7K ﹤0.01%
15,583
-113,607
-88% -$60.5K
AIOS
12245
AIOS Tech
AIOS
$39M
$7K ﹤0.01%
+71
New +$10.6K
PHIO icon
12246
CALL
Phio Pharmaceuticals
PHIO
$12.7M
$7K ﹤0.01%
+107
New +$8.11K
CNSY
12247
Cerenome, Inc. Common Stock
CNSY
$25.3M
$7K ﹤0.01%
+45
New +$10K
RKDA icon
12248
CALL
Arcadia Biosciences
RKDA
$1.36M
$7K ﹤0.01%
+325
New +$11.1K
SATLW icon
12249
Satellogic Inc Warrant
SATLW
$75.1M
$7K ﹤0.01%
23,961
+237
+1% +$105
SOGP
12250
PUT
Sound Group
SOGP
$47.1M
$7K ﹤0.01%
+1,160
New +$12.1K
488 489
490
491 492

Similar funds

Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Ken Griffin's Q3 2022 Portfolio in Review

As of Q3 2022, Ken Griffin held 14,356 positions worth $439B, up 13% from $390B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Ken Griffin deployed $65.7B of net new capital in Q3 2022, opening 1,622 new positions and adding to 5,458 existing holdings. Its largest new stake was SentinelOne: 4,426,634 shares worth $113M.

By sector, the portfolio is most concentrated in Technology at 3.1% of assets, up from 2.8% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Meta Platforms (Facebook), an estimated $349M trimmed.

  • Ken Griffin's largest Q3 2022 buy was SentinelOne: 4,426,634 shares worth $113M.
  • Ken Griffin added most to Apple in Q3 2022, an estimated $703M increase.
  • Ken Griffin's biggest Q3 2022 reduction was Meta Platforms (Facebook), cutting an estimated $349M.
  • Ken Griffin fully exited Regions Financial in Q3 2022, selling an estimated $207M.
  • Ken Griffin's ten largest holdings make up 34% of its $439B portfolio in Q3 2022.
  • Ken Griffin opened 1,622 new positions and closed 1,858 in Q3 2022.
  • Ken Griffin's portfolio value rose 13% quarter-over-quarter to $439B.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.